

BioSpect


the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Beyond Antibiotics: How Phage Therapy Is Fighting the Superbug Crisis

02 June 2026 | Views | By Sneha Salunke, Freelancer

Regulatory bodies are still establishing frameworks for a treatment that is dynamic and custom-tailored to individuals



Every year, drug-resistant bacteria kill over a million people worldwide and the numbers are increasing. Antibiotics, the drugs we have relied on since the 1940s, are becoming increasingly ineffective. The answer, it turns out, has existed for billions of years: bacteriophages, viruses that specifically infect and lyse bacterial cells. Scientists are now racing to harness their therapeutic potential, and emerging evidence suggests they could redefine our approach to infectious disease management.

The Antibiotic Resistance Crisis: Why We Need Alternatives

The golden age of antibiotic discovery, which once yielded over 40 distinct classes, has stalled. Today, the pipeline faces severe bottlenecks; out of thousands of preclinical molecules, fewer than five typically achieve regulatory approval. This high attrition rate, combined with rapid resistance, makes capital investment commercially unviable for pharmaceutical companies. While development stagnates, the threat accelerates. The evolution of multidrug-resistant (MDR) and pan-drug-resistant (PDR) pathogens notably the WHO's high-priority ESKAPE group consistently outpaces new drugs. Left unaddressed, this will precipitate a post-antibiotic era where routine infections become lethal, necessitating an immediate shift toward alternatives like bacteriophage therapy.

What Are Bacteriophages? Nature's Original Bacteria Killers

Bacteriophages are viruses that target and destroy bacterial cells without affecting mammalian tissue. Unlike broad-spectrum antibiotics, which act as blunt chemical agents causing collateral damage to the host microbiome, phages are highly specific obligate parasites. They bind to precise surface receptors on Gram-positive or Gram-negative bacterial walls in a conserved receptor-mediated adsorption. Once attached, a lytic phage ejects its genetic material into the host cell, hijacking its metabolic machinery to manufacture viral progeny.

Because phages reproduce exponentially at the infection site, they offer a self-limiting dosage; the treatment multiplies where bacteria are present and clears out once the host population is gone. Furthermore, unlike static drugs, phages possess an evolutionary capacity to mutate alongside the host when a bacterium alters its receptors to develop resistance.

However, therapy must strictly utilise obligate lytic phages. Temperate phages risk lysogenic conversion, where integrated prophages transfer virulence factors or resistance genes to the host genome. Properly screened lytic phages can degrade biofilms and work synergistically with the immune system to fight pan-drug-resistant infections.

How Phage Therapy Works: The Lytic Life

The therapeutic success of bacteriophage treatment relies entirely on the strictly lytic replication cycle, which systematically destroys target bacteria from within. The process begins with phage adsorption, where viral tail structures bind to specific receptors on the bacterial surface. Upon attachment, the tail tube penetrates the cell envelope to eject genomic DNA directly into the host cytoplasm. Once inside, the viral genome hijacks the cell's framework, forcing the bacterium to stop its own synthesis and manufacture viral structural proteins and new phage genomes instead.

To release these newly assembled particles, the virus must break through the durable bacterial cell envelope. This destruction is driven by two main types of phage-encoded proteins: polysaccharide depolymerases and virion-associated peptidoglycan hydrolases (VAPGH). The depolymerases degrade the outer protective capsule and extracellular matrix of biofilms, while the hydrolases directly break down the internal peptidoglycan layer. This coordinated enzymatic attack destabilises the cell wall, inducing osmotic lysis. The bacterium bursts, releasing hundreds of progeny virions into the immediate microenvironment to infect neighboring pathogens.

Phages vs Antibiotics: Key Differences

Unlike systemic, broad-spectrum antibiotics that eliminate beneficial gut microbiota alongside pathogens, phages are precise biological entities targeting only the specific bacterial strain causing infection. This live nature completely changes dosing; while chemical drugs break down over time, phages multiply exponentially at the infection site, creating a natural feedback loop that scales up during infection and fades once it clears. Most importantly, if a bacterium alters its surface receptors to escape, phages can naturally mutate alongside it to maintain the attack and evolutionary flexibility a fixed chemical drug simply cannot match.

Concluding Remarks and Future Outlook

The looming threat of antibiotic resistance is a current medical emergency requiring an immediate expansion of our antimicrobial toolkit. As traditional drug pipelines dry up, bacteriophage therapy stands out as a biologically adaptive strategy, though moving it to standard clinical care brings real-world hurdles. Because wild phages are naturally occurring organisms,

they cannot be patented, disrupting the standard pharmaceutical business model and forcing intellectual property to focus on engineering or processing techniques instead.

Additionally, regulatory bodies are still establishing frameworks for a treatment that is dynamic and custom-tailored to individuals, though recent trials confirm that safety and treatment outcome remains positive. Despite these complexities, scaling phage therapy offers massive clinical returns, creating specialised biotechnology jobs and serving as a vital line of defense through phage-antibiotic synergy.

Sneha Salunke, Freelancer